脑与脊髓肿瘤神经外科患者日常临床环境中院内感染、再次手术及不良事件预测评分的开发与验证
研究基于2017年9月至2019年5月治疗的1000例脑与脊髓肿瘤患者,开发并内部验证了三个风险评分:NoInfECT预测院内感染、LEUCut预测30天非计划再次手术、LINC预测任何不良事件,各评分在受试者工作特征曲线分析中显示出满意的区分度(AUC≥0.7)。
要点
- 1000例患者中,30天非计划再次手术发生率为6.8%,院内感染为7.4%,任何不良事件为14.5%。
- NoInfECT评分将院内感染风险分为低危1.8%、中危8.1%、高危26.0%(p<0.001)。
- LEUCut评分将30天非计划再次手术风险分为低危2.2%、中危6.8%、高危13.5%(p<0.001)。
核心结论
- 所提出的风险评分能有效预测不良事件发生的可能性,可用于比较不同提供者的医疗质量,并为外科医生分配术前护理提供指导。
研究设计与样本
- 开发半自动登记系统,纳入2017年9月至2019年5月期间治疗的所有脑与脊髓肿瘤患者,共1000例。
- 患者被分为开发队列和验证队列,采用多变量逻辑回归模型基于β系数分配分值以开发风险评分,并进行内部验证。
主要发现
- 30天非计划再次手术发生率为6.8%,院内感染发生率为7.4%,任何不良事件发生率为14.5%。
- 风险评分包含急诊入院、护理等级、ECOG体能状态和入院时炎症标志物等变量。
- NoInfECT评分预测院内感染发生率:低危1.8%、中危8.1%、高危26.0%(p<0.001)。
- LEUCut评分预测30天非计划再次手术:低危2.2%、中危6.8%、高危13.5%(p<0.001)。
- LINC评分预测任何不良事件:低危7.6%、中危15.7%、高危49.5%(p<0.001)。
关键数值与推荐
- NoInfECT评分低危1.8%、中危8.1%、高危26.0%(p<0.001)。
- LEUCut评分低危2.2%、中危6.8%、高危13.5%(p<0.001)。
- LINC评分低危7.6%、中危15.7%、高危49.5%(p<0.001)。
- 在受试者工作特征曲线分析中,三个评分系统均显示出满意的区分度(AUC≥0.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Various quality indicators are currently under investigation, aiming at measuring the quality of care in neurosurgery; however, the discipline currently lacks practical scoring systems for accurately assessing risk. The aim of this study was to develop three accurate, easy-to-use risk scoring systems for nosocomial infections, reoperations, and adverse events for patients with cerebral and spinal tumors. METHODS: The authors developed a semiautomatic registry with administrative and clinical data and included all patients with spinal or cerebral tumors treated between September 2017 and May 2019. Patients were further divided into development and validation cohorts. Multivariable logistic regression models were used to develop risk scores by assigning points based on β coefficients, and internal validation of the scores was performed. RESULTS: In total, 1000 patients were included. An unplanned 30-day reoperation was observed in 6.8% of patients. Nosocomial infections were documented in 7.4% of cases and any adverse event in 14.5%. The risk scores comprise variables such as emergency admission, nursing care level, ECOG performance status, and inflammatory markers on admission. Three scoring systems, NoInfECT for predicting the incidence of nosocomial infections (low risk, 1.8%; intermediate risk, 8.1%; and high risk, 26.0% [p < 0.001]), LEUCut for 30-day unplanned reoperations (low risk, 2.2%; intermediate risk, 6.8%; and high risk, 13.5% [p < 0.001]), and LINC for any adverse events (low risk, 7.6%; intermediate risk, 15.7%; and high risk, 49.5% [p < 0.001]), showed satisfactory discrimination between the different outcome groups in receiver operating characteristic curve analysis (AUC ≥ 0.7). CONCLUSIONS: The proposed risk scores allow efficient prediction of the likelihood of adverse events, to compare quality of care between different providers, and further provide guidance to surgeons on how to allocate preoperative care.
引用
- Lohmann S, Brix T, Varghese J, et al. Development and validation of prediction scores for nosocomial infections, reoperations, and adverse events in the daily clinical setting of neurosurgical patients with cerebral and spinal tumors. J Neurosurg. 2020. PMID: 32197255. doi:10.3171/2020.1.JNS193186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。